Загрузка...
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis
INTRODUCTION: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. In clinical trials, treated patients showed improved pulmonary function, reduced pulmonary exacer...
Сохранить в:
| Опубликовано в: : | Expert Opin Drug Saf |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209511/ https://ncbi.nlm.nih.gov/pubmed/28846049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1372419 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|